



PB 14 of 2025

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 2)

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the *National Health Act 1953*.

Dated 24 February 2025

REBECCA RICHARDSON
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division

Contents

1	Name.....	1
2	Commencement.....	1
3	Authority	1
4	Schedules.....	1
	Schedule 1—Amendments	2
	<i>National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).</i>	<i>2</i>

1 Name

- (1) This instrument is the *National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 2)*.
- (2) This instrument may also be cited as PB 14 of 2025.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. <i>The whole of this instrument</i>	<i>1 March 2025</i>	<i>1 March 2025</i>

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 84AAA(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

[1] Schedule 1, after entry for Donepezil in the form Tablet containing donepezil hydrochloride 10 mg

insert:

Drospirenone with ethinylestradiol	Pack containing 21 tablets 3 mg drospirenone with 30 micrograms ethinylestradiol and 7 inert tablets	20	3	3
	Pack containing 24 tablets 3 mg drospirenone with 20 micrograms ethinylestradiol (as betadex clathrate) and 4 inert tablets	20	3	3

[2] Schedule 1, after entry for Estradiol in the form Tablet containing estradiol valerate 2 mg

insert:

	Transdermal gel (pump pack) 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses	20	1	5
--	---	----	---	---

[3] Schedule 1, after entry for Estradiol in the form Transdermal patches 1.56 mg, 8

insert:

	Transdermal patches 1.56 mg, 24 (Sandoz) (S19A)	20	1	1
--	---	----	---	---

[4] Schedule 1, after entry for Estradiol with norethisterone in the form Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8

insert:

	Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 (S19A)	20	1	5
--	---	----	---	---

[5] Schedule 1, after entry for Estradiol with norethisterone in the form Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8

insert:

	Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A)	20	1	5
--	---	----	---	---

[6] Schedule 1, after entry for Probenecid

insert:

Progesterone	Capsule 100 mg	20	30	5
Progesterone and estradiol	Pack containing 30 capsules progesterone 100 mg (micronised) and transdermal gel (pump pack) estradiol 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses	20	1	5

[7] Schedule 2, after entry for Acarbose in the form Tablet 50 mg

insert:

Tablet 50 mg (S19A)	50	180	5
---------------------	----	-----	---

[8] Schedule 2, after entry for Acarbose in the form Tablet 100 mg

insert:

Tablet 100 mg (S19A)	50	180	5
----------------------	----	-----	---

[9] Schedule 2, after entry for Doxycycline in the form Tablet 50 mg (as monohydrate)

insert:

Duloxetine	Capsule 60 mg (as hydrochloride)	50	56	2
------------	----------------------------------	----	----	---

[10] Schedule 2, after entry for Estradiol in the form Tablet containing estradiol valerate 2 mg

insert:

Transdermal gel (pump pack) 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses	50	2	5
---	----	---	---

[11] Schedule 2, after entry for Estradiol with norethisterone in the form Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8

insert:

Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 (S19A)	50	2	5
---	----	---	---

[12] Schedule 2, after entry for Estradiol with norethisterone in the form Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8

insert:

Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A)	50	2	5
---	----	---	---

[13] Schedule 2, after entry for Fluoxetine

insert:

Tablet, dispersible, 20 mg (as hydrochloride)	50	56	2
---	----	----	---

[14] Schedule 2, entry for Gliclazide

insert as first entry:

Tablet 30 mg (modified release)	50	200	5
---------------------------------	----	-----	---

[15] Schedule 2, after entry for Probenecid

insert:

Progesterone	Capsule 100 mg	50	60	5
Progesterone and estradiol	Pack containing 30 capsules progesterone 100 mg (micronised) and transdermal gel (pump pack) estradiol 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses	50	2	5